Checked
Incyte Corp
Nasdaq: INCY · Services-Commercial Physical & Biological Research · Wilmington, DE
- Revenue
- $5.14B
- +21.2% vs. prior year
- Net income
- $1.29B
- 25.0% net margin
- Total assets
- $6.96B
- Diluted EPS
- $6.41
Company details
As reported to the SEC
- SEC CIK
- 879169
- Stock
- Nasdaq: INCY
- Legal Entity Identifier (LEI)
- 549300Z4WN6JVZ3T4680
- Headquarters
- 1801 Augustine Cut-Off, Wilmington, DE 19803
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (302) 498-6700
- Employer ID (EIN)
- 94-3136539
- Last annual report
- 02/10/2026
- Last quarterly report
- 07/28/2026
Formerly: INCYTE INC (until 03/28/2003); INCYTE GENOMICS INC (until 02/25/2003); INCYTE PHARMACEUTICALS INC (until 04/18/2000)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.7B | $3.39B | $2.99B |
| Operating income | $1.51B | $61.37M | $620.5M | $579.4M | $585.8M |
| Net income | $1.29B | $32.62M | $597.6M | $340.7M | $948.6M |
| Diluted earnings per share | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
| Research and development | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B |
| Total assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B |
| Total liabilities | $1.79B | $2B | $1.59B | $1.47B | $1.16B |
| Shareholders' equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B |
| Cash and cash equivalents | $3.1B | $1.69B | $3.21B | $2.95B | $2.06B |
| Cash from operations | $1.41B | $335.3M | $496.5M | $969.9M | $749.5M |
Federal and state records filed under the name Incyte Corp
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Incyte CorporationWilmington, DE | 33 | 3 |
Subsidiaries
27 companies that Incyte Corp owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Escient Pharmaceuticals Australia Pty Ltd | SEC 10-K |
| Escient Pharmaceuticals, Inc. | SEC 10-K |
| Incyte Biosciences (Shanghai) Co., Ltd. | SEC 10-K |
| Incyte Biosciences Australia Pty Ltd | SEC 10-K |
| Incyte Biosciences Austria GmbH | SEC 10-K |
| Incyte Biosciences Benelux B.V. | SEC 10-K |
| Incyte Biosciences Canada Corporation | SEC 10-K |
| Incyte Biosciences Denmark ApS | SEC 10-K |
| Incyte Biosciences Distribution B.V. | SEC 10-K |
| Incyte Biosciences Finland Oy | SEC 10-K |
| Incyte Biosciences France | SEC 10-K |
| Incyte Biosciences Germany GmbH | SEC 10-K |
| Incyte Biosciences Iberia S.L. | SEC 10-K |
| Incyte Biosciences International S.à r.l. | SEC 10-K |
| Incyte Biosciences Italy S.R.L. | SEC 10-K |
| Incyte Biosciences Japan G.K. | SEC 10-K |
| Incyte Biosciences Nordic AB | SEC 10-K |
| Incyte Biosciences Norway AS | SEC 10-K |
| Incyte Biosciences Poland sp. z o.o. | SEC 10-K |
| Incyte Biosciences Technical Operations S.à r.l. | SEC 10-K |
| Incyte Biosciences UK Ltd | SEC 10-K |
| Incyte International Holdings S.à r.l. | SEC 10-K |
| Incyte Real Estate Holdings I LLC | SEC 10-K |
| Incyte Real Estate Holdings II LLC | SEC 10-K |
| Incyte Research Institute LLC | SEC 10-K |
| Jidochem S.à r.l. | SEC 10-K |
| Villaris Therapeutics Inc. | SEC 10-K |
Recent filings
107 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| 8-KOther events | 08/31/2026 | 08/31/2026 |
| 10-QQuarterly report | 07/28/2026 | 06/30/2026 |
| 8-KResults of operations | 07/28/2026 | 07/28/2026 |
| 8-KOther events | 07/06/2026 | 07/06/2026 |
| 8-KOther events | 06/22/2026 | 06/22/2026 |
| 8-KShareholder vote results | 06/09/2026 | 06/08/2026 |
| 8-KOther events | 06/08/2026 | 06/08/2026 |
| DEFA14AAdditional proxy materials | 05/27/2026 | None |
| SCHEDULE 13G/AOwnership report (5% holder, passive, amended) | 05/14/2026 | None |
| SCHEDULE 13D/AOwnership report (5% holder, active, amended) | 05/11/2026 | None |
| SCHEDULE 13GOwnership report (5% holder, passive) | 04/30/2026 | None |
| ARSAnnual report to shareholders | 04/28/2026 | 12/31/2025 |
| DEFA14AAdditional proxy materials | 04/28/2026 | None |
| DEF 14AProxy statement | 04/28/2026 | 12/31/2025 |
| 10-QQuarterly report | 04/28/2026 | 03/31/2026 |
| 8-KResults of operations | 04/28/2026 | 04/28/2026 |
| 8-KDirector or officer change | 03/30/2026 | 03/26/2026 |
| SCHEDULE 13G/AOwnership report (5% holder, passive, amended) | 03/27/2026 | None |
| 8-KDirector or officer change | 03/26/2026 | 03/25/2026 |
| 8-KOther events | 03/06/2026 | 02/27/2026 |
141 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Incyte Corp in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other services-commercial physical & biological research
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| IQVIA Holdings Inc.IQV | Durham, NC | $16.31B | $1.36B |
| Icon PLCICLR | Dublin 18, Ireland | $8.25B | $229.3M |
| Charles River Laboratories International, Inc.CRL | Wilmington, MA | $4.02B | -$144.3M |
| Medpace Holdings, Inc.MEDP | Cincinnati, OH | $2.53B | $451.1M |
| NRC HealthNRC | Lincoln, NE | $137.4M | $11.6M |
| Maxcyte, Inc.MXCT | Rockville, MD | $33.03M | -$44.63M |
| OmniAb, Inc.OABI | Emeryville, CA | $18.67M | -$64.78M |
| Foxo Technologies Inc.FOXO | West Palm Beach, FL | $16.37M | -$12.43M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Incyte Corp's CIK number?
- Incyte Corp's SEC Central Index Key (CIK) is 879169.
- What is Incyte Corp's stock ticker?
- Incyte Corp trades as Nasdaq: INCY.
- What was Incyte Corp's revenue?
- Incyte Corp reported revenue of $5.14B for the fiscal year ended Dec 31, 2025, +21.2% from the year before.
- When does Incyte Corp's fiscal year end?
- Incyte Corp's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Incyte Corp headquartered?
- Incyte Corp's principal executive office on file with the SEC is in Wilmington, DE.
- What companies does Incyte Corp own?
- Incyte Corp lists 27 subsidiaries in its SEC filings and other public records, including Escient Pharmaceuticals Australia Pty Ltd, Escient Pharmaceuticals, Inc., Incyte Biosciences (Shanghai) Co., Ltd.
- Does Incyte Corp sponsor H-1B visas?
- Department of Labor records show 33 certified H-1B filings and 3 certified PERM filings under the name Incyte Corp.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026